## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($238.00)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 3, Bearish: 1)

**1. Humana Inc. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251203T163000 | Bullish | Relevance: 100%
- Humana Inc. (HUM) stock experienced a significant rise of 6.18% on a strong trading day for the overall stock market. This increase to $256.92 broke a three-day losing streak for the company. The S&P 500 Index and the Dow Jones Industrial Average also saw gains, indicating a favorable market session.

**2. Berman Tabacco Announces Investigation of Humana, Inc. (NYSE:HUM)**
- Source: GlobeNewswire | 20251202T153100 | Bearish | Relevance: 100%
- Berman Tabacco has announced an investigation into potential stockholder claims against Humana, Inc. (NYSE:HUM) following allegations that the company paid illegal kickbacks to insurance brokers like SelectQuote between 2016 and 2021. These alleged kickbacks, possibly totaling up to $250 million, were intended to steer insurance customers towards Humana's Medicare offerings. The investigation will examine whether Humana's board members, officers, and/or directors breached their fiduciary duties, especially after shares declined approximately 3% upon the unsealing of the complaint in May 2025.

**3. Humana Inc Reaffirms 2025 Earnings Guidance**
- Source: TradingView | 20251202T032530 | Bullish | Relevance: 100%
- Humana Inc. reaffirmed its 2025 earnings guidance during investor meetings on December 1, 2025. The company projected a reaffirmed FY 2025 EPS guidance of $12.26 and an adjusted EPS of $17.00. Potential changes are expected in GAAP EPS due to strategic initiatives.

**4. Humana appeals Medicare Advantage star ratings loss to 5th Circuit**
- Source: Healthcare Dive | 20251201T162133 | Somewhat-Bearish | Relevance: 100%
- Humana is appealing its Medicare Advantage star ratings loss to the 5th Circuit Court of Appeals, continuing its legal battle against the government's recalculation of scores that could impact its bonus payments by an estimated $1 billion or more in 2026. The insurer maintains that the Centers for Medicare & Medicaid Services (CMS) acted arbitrarily in downgrading its quality scores based on unsuccessful customer service calls. This move follows multiple setbacks in lower courts and comes amidst proposed changes by the Trump administration to Medicare Advantage star ratings measures, including one focused on call center performance.

**5. New Insurance Coverage Resource Released by Muse Treatment Exploring Humana Inpatient Rehab Benefits**
- Source: The Topeka Capital-Journal | 20251201T110829 | Somewhat-Bullish | Relevance: 100%
- Muse Treatment has released a new educational resource detailing how Humana insurance covers inpatient rehab for addiction treatment. This publication, available on their website, clarifies Humana's policies, medical necessity criteria, and verification procedures to help patients understand coverage for substance-use disorders. The resource aims to provide neutral, evidence-supported information to aid individuals navigating treatment options and insurance benefits.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-25 | Barclays | $234 | $245 | -4% |
| 2025-11-10 | Truist Securiti | $285 | $300 | -5% |
| 2025-11-07 | Deutsche Bank | $231 | $250 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-25 | Barclays | main | Equal-Weight |
| 2025-11-10 | Truist Securiti | main | Hold |
| 2025-11-07 | Deutsche Bank | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.14M) |
| Sells | 6 ($1.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +6.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Balance sheet: strong liquidity (2.0x). Analyst sentiment negative (3 target cuts vs 0 raises). Insider selling cluster ($1.5M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $31.1B |
| Beta | 0.47 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 20.6 |
| Current P/E | 15.1 |
| YoY Growth | -27.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.2% to 4.8% (+6.0% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 85th percentile. MRS_5 at 3.7% confirms short-term momentum alignment. AM_20 at 6.8% shows strong absolute momentum above own 20MA. Outperforming sector by 5.1pp, stock-specific strength. Below SMA200 (0.99x), long-term trend not supportive. MACD histogram positive (3.15), confirming momentum. RSI neutral at 55. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.84% (CS: 86) | Strong |
| RSI_14 | 55.2 | Neutral |
| MACD Histogram | 3.15 | Bullish |
| vs SMA20 | 1.068x | Above |
| vs SMA50 | 0.978x | Below |
| vs SMA200 | 0.993x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $256.92
- **Stop Loss:** $238.00 (7.4% risk)
- **Target:** $294.76 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 50
- **Position Value:** $12,846.00
- **Portfolio %:** 12.85%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*